Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Kathleen Turnbull"'
Autor:
Ruben A. Mesa, Yun Su, Adrien Woolfson, Josef T. Prchal, Kathleen Turnbull, Elias Jabbour, Robyn Scherber, Alan L. Shields, Meaghan Krohe, Funke Ojo, Farrah Pompilus, Joseph C. Cappelleri, Claire Harrison
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-16 (2019)
Abstract Background The goal of the research reported here was to understand the patient experience of living with myelofibrosis (MF) and establish content validity of the Modified Myeloproliferative Neoplasm Symptom Assessment Diary (MPN-SD). Method
Externí odkaz:
https://doaj.org/article/10037569fd8641a283e259003be29fc8
Autor:
Wells A. Messersmith, Charles Zacharchuk, Kathleen Turnbull, Eric Leip, Poe-Hirr Hsyu, Nathalie Bardy-Bouxin, Shefali Agarwal, Richat Abbas, Gregory M. Springett, Elena G. Chiorean, Philip J. Gold, Mitesh J. Borad, Barbara J. Gitlitz, Mansoor N. Saleh, Smitha S. Krishnamurthi, Adil I. Daud
PDF file - 89K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4587c6678ceb7f5636d4a877514e37
https://doi.org/10.1158/1078-0432.22444170
https://doi.org/10.1158/1078-0432.22444170
Autor:
Robyn M. Scherber, Ruben A. Mesa, Farrah Pompilus, Kathleen Turnbull, Elias Jabbour, Alan L. Shields, Josef T. Prchal, Funke Ojo, Adrien Woolfson, Yun Su, Meaghan Krohe, Claire N. Harrison, Joseph C. Cappelleri
Publikováno v:
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-16 (2019)
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-16 (2019)
Background The goal of the research reported here was to understand the patient experience of living with myelofibrosis (MF) and establish content validity of the Modified Myeloproliferative Neoplasm Symptom Assessment Diary (MPN-SD). Methods Qualita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3485603d3063ca389711464264802fe8
https://doi.org/10.1186/s12955-019-1121-1
https://doi.org/10.1186/s12955-019-1121-1
Autor:
Tim H. Brümmendorf, Kathleen Turnbull, Eric Leip, Ewa Matczak, Hanna Jean Khoury, Nathalie Bardy-Bouxin, Mark Shapiro, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim, Anna G. Turkina
Publikováno v:
American Journal of Hematology
Long‐term efficacy and safety of bosutinib (≥4 years follow‐up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated‐phase [AP, n = 79] chronic myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cea9bb858c175026ab1fdcedfe8d3827
https://doi.org/10.1002/ajh.24034
https://doi.org/10.1002/ajh.24034
Autor:
Sarit Assouline, Dong-Wook Kim, Vikram Mathews, Jie Jin, Zhi Xiang Shen, Edo Vellenga, H. Jean Khoury, Ricardo Pasquini, Andrey Zaritskey, Hagop M. Kantarjian, Simon Durrant, Tim H. Brümmendorf, Jorge E. Cortes, Anna G. Turkina, Francisco Cervantes, Carlo Gambacorti-Passerini, Kathleen Turnbull, Eric Leip, Tamas Masszi, Virginia Kelly, Nadine Besson
Publikováno v:
American Journal of Hematology, 89(7), 732-742. Wiley
American Journal of Hematology
American Journal of Hematology
Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c8b08db792a53b8ad392d6b79e559d
https://hdl.handle.net/11370/b17f07ea-07ec-4d56-8bf0-d0be982b0cc1
https://hdl.handle.net/11370/b17f07ea-07ec-4d56-8bf0-d0be982b0cc1
Autor:
Carlo Gambacorti-Passerini, Philippe Schafhausen, Jeffrey H. Lipton, Maureen G. Conlan, Dong-Wook Kim, Hagop M. Kantarjian, Mark Shapiro, Jorge E. Cortes, Hanna Jean Khoury, Eric Leip, Kathleen Turnbull, Tim H. Brümmendorf
Publikováno v:
British journal of haematology : BJH 172(1), 97-110 (2016). doi:10.1111/bjh.13801
British Journal of Haematology
British Journal of Haematology
British journal of haematology : BJH 172(1), 97-110 (2016). doi:10.1111/bjh.13801
Published by Wiley-Blackwell, Oxford [u.a.]
Published by Wiley-Blackwell, Oxford [u.a.]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391d28ca5929c5aead1c4601cf9ad466
Autor:
Elena G. Chiorean, Barbara J. Gitlitz, Mitesh J. Borad, Nathalie Bardy-Bouxin, Wells A. Messersmith, Richat Abbas, Charles Zacharchuk, Kathleen Turnbull, Philip J. Gold, Adil Daud, Poe-Hirr Hsyu, Gregory M. Springett, Smitha S. Krishnamurthi, Shefali Agarwal, Mansoor N. Saleh, Eric Leip
Publikováno v:
Clinical Cancer Research. 18:1092-1100
Purpose: Bosutinib, a potent ATP-competitive, quinolinecarbonitrile Src/Abl kinase inhibitor, was tested in this first-in-human phase I trial in patients with advanced solid tumor malignancies. Patients and Methods: This trial was conducted in 2 part
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b739b676b1699f8aa13ab1b35c6645
https://doi.org/10.1158/1078-0432.ccr-11-2378
https://doi.org/10.1158/1078-0432.ccr-11-2378
Autor:
Charles Zacharchuk, Ladan Duvillie, Meritxell Bellet, Kathleen Turnbull, Tomasz Sarosiek, Beverly Moy, István Láng, Patrick Neven, Fabienne Lebrun, Nathalie Bardy-Bouxin, Eric Leip, Louis W.C. Chow, Paul E. Goss, Binghe Xu
Author Summary Background. Bosutinib is an oral, selective Src/Abl tyrosine kinase inhibitor with activity in breast cancer (BC). We evaluated bosutinib plus exemestane as second-line therapy in previously treated hormone receptor-positive (HR+) loca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca39110aa07b22204edaa36a9ea2eb63
https://europepmc.org/articles/PMC3983831/
https://europepmc.org/articles/PMC3983831/
Autor:
Mario Campone, Eric Leip, Emiliano Calvo, Kathleen Turnbull, Antonio Calles, Nathalie Bardy-Bouxin, Ding Wang, Ladan Duvillie, Steven J. Isakoff
Publikováno v:
British Journal of Cancer
Background: This phase 1 study evaluated the maximum tolerated dose (MTD), safety, and efficacy of bosutinib (competitive Src/Abl tyrosine kinase inhibitor) plus capecitabine. Methods: Patients with locally advanced/metastatic breast, pancreatic, or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1443612d2b554332258bdae9664a0f8
https://pubmed.ncbi.nlm.nih.gov/25290090
https://pubmed.ncbi.nlm.nih.gov/25290090
Autor:
Richat Abbas, Eunice L. Kwak, Leena Gandhi, Shuchi Sumant Pandya, Sara M. Tolaney, Jean-Charles Soria, Kathleen Turnbull, Antoine Hollebecque, Geoffrey I. Shapiro, Mizue Krygowski, Rastislav Bahleda, Revathi Ananthakrishnan, Anna Berkenblit, James M. Cleary, Yali Liang
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(2)
Purpose Human epidermal growth factor (HER) –mediated signaling is critical in many cancers, including subsets of breast and lung cancer. HER family members signal via the phosphatidylinositide 3-kinase (PI3K) –AKT/protein kinase B–mammalian ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ffec2f9ce7696b7c38fbe3315aad632
https://pubmed.ncbi.nlm.nih.gov/24323038
https://pubmed.ncbi.nlm.nih.gov/24323038